Contact
Please use this form to send email to PR contact of this press release:
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
TO:
Please use this form to send email to PR contact of this press release:
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma
TO: